Purvalanol A, 98%, a potent CDK inhibitor

Name: Purvalanol A, 98%, a potent CDK inhibitor | 212844-53-6
Brand: J&K Chemical
SKU: JK338303_5_MG
Price: 106.1 USD
Availability: OutOfStock

Cat. No JK338303_5_MG

Vendor: J&K Chemical

Product Information

Product Name

Purvalanol A, 98%, a potent CDK inhibitor

Brand Name

J&K

Product Number

338303

CAS

212844-53-6

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

456214

IUPAC Name

(2R)-2-6-(3-chloroanilino)-9-propan-2-ylpurin-2-ylamino-3-methylbutan-1-ol

InChI Key

PMXCMJLOPOFPBT-HNNXBMFYSA-N

SMILES

CC(C)C@H(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=CC=C3)Cl

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data

Publication Name: Nucleic Acids Research

Publication Date: 2024-11-22

DOI: 10.1093/nar/gkae1075

EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2024-02-05

DOI: 10.1016/j.ejmech.2023.116098

TTD: Therapeutic Target Database describing target druggability information

Publication Name: Nucleic Acids Research

Publication Date: 2023-09-15

DOI: 10.1093/nar/gkad751

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma

Publication Name: Cancer Letters

Publication Date: 2023-08-01

DOI: 10.1016/j.canlet.2023.216284

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Publication Name: Science Translational Medicine

Publication Date: 2023-06-21

DOI: 10.1126/scitranslmed.add7872

Purvalanol A, 98%, a potent CDK inhibitor

Product Information

General Information

Safety Information

References Data Source From Pubchem

BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data

EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model

TTD: Therapeutic Target Database describing target druggability information

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer